January 24, 2019
Oncopeptides has completed a directed share issue of approximately SEK 546 million
January 24, 2019 - Regulatory press release
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRA...
Read more
Read more
January 17, 2019
Targovax granted European Patent for mutant-RAS neoantigen platform lead products
Extends IP protection of TG01 and TG02 until 06.05.2034
Oslo, 17 January 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focuse...
Read more
Read more
January 11, 2019
Actavis infringes Orexo’s long term Zubsolv® US patent ´330
Uppsala, Sweden – January 11, 2019 – Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Unit...
Read more
Read more
January 7, 2019
Modus Therapeutics completes enrollment of randomized, placebo-controlled Phase II clinical trial evaluating sevuparin for management of Acute Vaso-Occlusive Crisis in SCD patients
STOCKHOLM, SWEDEN – 07 January 2019: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell diseas...
Read more
Read more
January 7, 2019
Aprea Therapeutics Announces Presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
BOSTON and STOCKHOLM, Jan. 7, 2019 /PRNewswire/ -- Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting t...
Read more
Read more
January 7, 2019
Positive results from human PK study assessing Orexo’s new intranasal naloxone formulations for opioid overdose reversal
Uppsala, Sweden – January 7, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces positive results f...
Read more
Read more
January 4, 2019
BONESUPPORT appoints Annelie Aava Vikner as Executive Vice President Global Marketing & Communications
Lund, Sweden, 8:00 CET, January 4 2019 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that...
Read more
Read more
January 4, 2019
Rainier Therapeutics Expands Leadership Team to Prepare for Late-Stage Clinical Trials
SAN LEANDRO, Calif., January 3, 2019
— Rainier Therapeutics, Inc., a privately-held clinical
stage drug development company focused on helping patients in the high unmet need...
Read more
Read more
January 2, 2019
Nordic Nanovector appoints Mark Wright as Head of Manufacturing
Oslo, Norway, 2 January 2019
Nordic Nanovector ASA (OSE: NANO) announces the appointment of Dr Mark Wright as Head of Manufacturing. He joins the company today a...
Read more
Read more
December 19, 2018
Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada
Strongbridge Used Portion of $145 Million Upfront Cash Payment from Novo Nordisk to Fully Repay Outstanding Debt
DUBLIN, Ireland and TREVOSE, Pa., Dec. 19, 2018 (GLOBE NEWSWIR...
Read more
Read more